前交叉韧带重建术后第一年炎症与软骨基质代谢血清生物标志物的纵向变化
这项队列研究纳入33例ACL损伤患者和33名匹配未损伤对照,随访至ACLR术后12个月,检测MCP-1、MMP-3、COMP和C2C:CPII。结果显示炎症与软骨相关标志物在术后第一年持续异常,提示生物学反应并未在重建和标准康复后完全消退。
要点
- ACL损伤者MCP-1在所有ACLR时间点均高于对照,且术后无变化。
- MMP-3从术前至术后6个月升高,但与对照无差异。
- C2C:CPII在术后12个月高于术前、术后6个月及未损伤对照。
核心结论
- 炎症和软骨相关生物标志物在ACLR术后第一年持续改变,提示生物学反应未因重建和标准康复而完全消退,并超出术后早期阶段。
研究设计与样本
- 队列研究,证据等级2;33例ACL损伤者(52%女性,平均年龄20.8±2.4岁)在ACLR术前、术后6和12个月评估,另设33名匹配未损伤对照。
- 采用酶联免疫吸附试验检测MCP-1、MMP-3、COMP和C2C:CPII血清浓度,使用线性混合效应模型及模型对比评估组间和时间点差异。
主要发现
- MCP-1在ACLR所有时间点均高于对照(所有Padj<.001),ACLR各时间点间无变化。
- MMP-3从术前至术后6个月升高(Padj<.001),但与对照在任何时间点均无差异。
- COMP在所有时间点均高于对照(所有Padj≤.021),ACLR各时间点间无变化。
- C2C:CPII在术后12个月高于术前和术后6个月(均Padj<.001),也高于未损伤对照(Padj=.001)。
- 术前MCP-1、MMP-3和COMP浓度与术后6和12个月浓度相关(所有P≤.006),C2C:CPII仅与12个月浓度相关(P=.018)。
关键数值与推荐
- MCP-1在ACLR所有时间点较对照升高,所有Padj<.001。
- MMP-3从术前至术后6个月升高,Padj<.001。
- COMP在所有时间点较对照升高,所有Padj≤.021。
- C2C:CPII术后12个月较术前和术后6个月升高,均Padj<.001;较未损伤对照升高,Padj=.001。
- 术前MCP-1、MMP-3和COMP与术后6和12个月浓度相关,所有P≤.006;C2C:CPII仅与12个月浓度相关,P=.018。
临床怎么用
- ACLR术后第一年炎症和软骨代谢标志物持续异常,提示临床评估不应仅局限于术后早期。
- 术前MCP-1、MMP-3和COMP浓度与术后6和12个月浓度相关,或可用于识别持续生物学异常风险。
- C2C:CPII在术后12个月升高,提示软骨降解与合成平衡在较晚时间点仍改变。
局限性
- 探索性事后模型评估了合并损伤状态的差异,但摘要未报告具体结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anterior cruciate ligament (ACL) injury initiates biological processes linked to joint tissue degeneration. The longitudinal time course of serum biomarkers reflecting inflammation and cartilage metabolism after ACL reconstruction (ACLR), particularly in comparison with uninjured controls, has not been characterized across the first postoperative year. HYPOTHESIS: Inflammatory (monocyte chemoattractant protein-1 [MCP-1]) and degradative (matrix metalloproteinase-3 [MMP-3]) biomarker concentrations would be elevated pre-ACLR and decrease over time, whereas cartilage turnover biomarker concentrations (cartilage oligomeric matrix protein [COMP] and type II collagen degradation-to-synthesis ratio [C2C:CPII]) would increase postoperatively. Also, pre-ACLR biomarker concentrations would be associated with concentrations at 6 and 12 months post-ACLR. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: A total of 33 individuals with ACL injuries (52% female; mean age, 20.8 ± 2.4 years) were evaluated pre-ACLR and at 6 and 12 months post-ACLR. A total of 33 matched uninjured controls were included. Serum concentrations of MCP-1, MMP-3, COMP, and C2C:CPII were assessed using enzyme-linked immunosorbent assays. Linear mixed-effects models with model-based contrasts were used to evaluate differences across groups and time points. ACLR-only linear mixed-effects regression models were used to assess associations between pre-ACLR and follow-up biomarker concentrations. Exploratory post hoc models evaluated differences by concomitant injury status. RESULTS: MCP-1 was elevated in individuals with ACL injuries compared with controls at all ACLR time points (all Padj < .001), with no change across ACLR time points. MMP-3 increased from pre-ACLR to 6 months post-ACLR (Padj < .001) but did not differ from controls at any time point. COMP was consistently greater in individuals with ACL injuries than in controls at all time points (all Padj≤ .021), with no changes across ACLR time points. C2C:CPII was greater at 12 months post-ACLR than at pre-ACLR and 6 months post-ACLR (both Padj < .001) and than in uninjured controls (Padj = .001). Pre-ACLR MCP-1, MMP-3, and COMP concentrations were associated with concentrations at both 6 and 12 months post-ACLR (all P≤ .006), whereas C2C:CPII was associated only with 12-month concentrations (P = .018). CONCLUSION: Inflammatory and cartilage-related biomarkers remain altered throughout the first year after ACLR, suggesting that the biological response is not fully resolved by reconstruction and standard rehabilitation but extends beyond the early postoperative period.
引用
- Lemus SA, Spang JT, Longobardi L, et al. Longitudinal Serum Biomarker Profiles of Inflammation and Cartilage Matrix Metabolism During the First Year After Anterior Cruciate Ligament Reconstruction. Am J Sports Med. 2026. PMID: 42929659. doi:10.1177/03635465261493224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。